leisure time -WSS

leisure time

author：entertainment 2025-09-03 07:45:50 - browse：7982

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

focus

WSS

Mystery swirls around US soldier who entered North Korea days ago, officials say

What American doctors can learn from their Israeli counterparts

How to protect patients from sexual assault

Are infertility treatments 'essential' during the Covid

Telehealth startups are trying to fill the menopause care vacuum

How generative AI is inspiring dreams of a health data revolution

leisure time

leisure time

Gilead needs Arcellx more than ever

leisure time

Cancer drug shortages should be causing more outrage

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Duchenne breakthrough therapy leaves behind pioneering families

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Judge denies Trump's request for new trial in E. Jean Carroll case

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Telehealth startups are trying to fill the menopause care vacuum

Medical leaders decry Supreme Court decision on affirmative action

'Make People Better': The CRISPR babies story you probably don't know

entertainment

A new House health package & hospitals’ new site

Telehealth startups are trying to fill the menopause care vacuum

NIH nominee Bertagnolli will get October confirmation hearing

After a decade, new Gardasil ad campaign gets it (mostly) right

A new House health package & hospitals’ new site

There’s a way to spot data fakery. All journals should be using it

focus

focus

Wikipedia

knowledge